Advertisement

Topics

Genocea Biosciences Company Profile

23:58 EDT 21st June 2018 | BioPortfolio

Genocea Biosciences was founded in 2006 to commercialize key breakthroughs in vaccine discovery and development. The Company’s proprietary T cell-directed antigen discovery program represents a broad platform with the potential to generate significant novel vaccines for multiple pathogens with high unmet medical need. Genocea is currently developing vaccines for Chlamydia trachomatis (a sexually transmitted disease agent causing an estimated 90 million cases worldwide), Streptococcus pneumoniae (pneumonia is the leading killer of children under the age of five worldwide), Herpes Simplex Virus Type 2 (45 million infected in the US)and Malaria (millions of cases each year) Genocea was recognized by BusinessWeek as one of the “World’s Most Intriguing Startups” for 2009. In 2008, Genocea was selected as “Best Vaccine Startup” at the World Vaccine Congress and was selected one of the 15 most exciting biotech startup companies by FierceBiotech. Genocea is backed by leading investors including Lux Capital Management, Polaris Venture Partners, S.R. One, the corporate venture arm of GlaxoSmithKline, Auriga Partners, Cycad Group, Morningside Ventures and Alexandria Real Estate Equities. Visit www.genocea.com for more information.


News Articles [650 Associated News Articles listed on BioPortfolio]

Genocea files IND for neoantigen cancer vaccine candidate

Genocea Biosciences has filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to initiate...Read More... The post Genocea files IND for neoantigen cancer v...

Reader Inquiry: Can Genocea Biosciences Really Pull Off The Makeover?

NEA Partner Ali Behbahani, M.D. Joins Genocea Biosciences’ Board of Directors

CAMBRIDGE, Mass., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Ali Behbahani,...

Genocea Biosciences: 200% Dilution, Hopelessness And Anger. Why Am I Still Holding? GEN-009 And ATLAS

Genocea Biosciences, Inc. Announces Pricing of $55 Million Concurrent Public Offerings

New Enterprise Associates (“NEA”) and Vivo Capital significant investors in financing Genocea intends to elect an NEA representative to Genocea board of directors CAMBRIDGE, Mass., Jan. 17,...

Genocea nets $51.7mm through public offerings of common and preferred shares

Genocea Biosciences Inc. (cancer vaccines) netted $51.7mm through concurrent public offerings. In one transaction, investors including New Enterprise Associates and Vivo Capital purchased 53.37mm comm...

Genocea Biosciences' (GNCA) CEO Chip Clark on Q4 2017 Results - Earnings Call Transcript

Genocea Biosciences, Inc. Announces Proposed Concurrent Public Offerings of Common Stock and Class A Warrants and Series A Convertible Preferred Stock and Class A Warrants

CAMBRIDGE, Mass., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company that discovers and develops novel cancer vaccines, announced today that it...

Drugs and Medications [13 Associated Drugs and Medications listed on BioPortfolio]

Naturally nova scotia hand sanitizer [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Natelle one [Azur Pharma, Inc.]

Natelle OneRx Prenatal Vitamin & Plant-Based DHA Now with 28 mg Iron

Natelle one [Azur Pharma, Inc.]

Natelle®OneRx Prenatal Vitamin & Plant-Based DHA

Clinical Trials [7 Associated Clinical Trials listed on BioPortfolio]

HepaStem Long-Term Safety Registry

All patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Bi...

Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

The purpose of this research is to determine if a subject's own bone marrow tissue can help regenerate bone in the area of his/her jaw where a tooth has been removed using Tissue Repair Ce...

Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data

We seek to improve the predictive accuracy of the nomogram to predict survival for patients with castrate mets disease through the addition of pathological data, the results of automated m...

Validation of Decipher Test in African American Men With Prostate Cancer - VANDAAM

The primary purpose of this study is to determine whether a tumor test recently developed by GenomeDx Biosciences known as Decipher® can predict aggressive prostate cancer with the same a...

Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic

The purpose of the expanded access program is to allow physicians to provide treatment with investigational drug, AB-PA01, for patients with serious or immediately life-threatening Pseudom...

Companies [351 Associated Companies listed on BioPortfolio]

Genocea Biosciences

Genocea Biosciences was founded in 2006 to commercialize key breakthroughs in vaccine discovery and development. The Company’s proprietary T cell-directed antigen disc...

Genocea Biosciences, Inc.

Genocea Biosciences is a vaccine discovery and development company targeting major infectious diseases with high unmet medical needs, in which T cell responses help confer protect...

Genocea Biosciences Inc.

Genocea Biosciences is a vaccine discovery and development company targeting major infectious diseases with high unmet medical needs, in which T cell response helps confer protect...

Genocea Biosciences, Inc. 

Hydra Biosciences, Inc.

Hydra Biosciences is a privately-held biopharmaceutical company based in Cambridge, Massachusetts, and develops drugs to treat pain, inflammation, anxiety and other diseases using...

More Information about "Genocea Biosciences" on BioPortfolio

We have published hundreds of Genocea Biosciences news stories on BioPortfolio along with dozens of Genocea Biosciences Clinical Trials and PubMed Articles about Genocea Biosciences for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Genocea Biosciences Companies in our database. You can also find out about relevant Genocea Biosciences Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record